EUVIMEDEUVIMED entdecken
Crossref

Evaluating the Associated Hyperuricemia Risk with Sodium-Glucose Cotransporter 2 Inhibitors: A Sequence Symmetry Analysis Using the Japanese Administrative Claims Database

Satoshi Yokoyama, Chihiro Nakagawa, Takaya Uno, Kouichi Hosomi

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b24-00330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Satoshi Yokoyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Drug Informatics, School of Pharmacy, Kindai University. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hyperuricemia, Databases, Factual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperuricemia is defined as high uric acid levels within the bloodstream and is commonly associated with gout, type 2 diabetes mellitus, and kidney disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel drugs that prevent glucose reabsorption; additionally, this drug has shown promising results in patients at risk of developing cardiovascular or renal complications by lowering uric acid levels. This study aimed to investigate the association between SGLT2i and hyperuricemia. Here, a self-controlled sequence symmetry analysis using the JMDC administrative claims database (January 2005 to September 2022) consisting of 12396 patients, who were newly prescribed both SGLT2i and hypouricemic agents, was conducted. Trend-adjusted sequence ratios (SR) at intervals of 6, 12, 18, and 24 months were calculated. Significant inverse signals across all intervals were observed between SGLT2i and hypouricemic agents, with the strongest effect observed in the 24-month interval [adjusted SR 0.52 (95% CI 0.49-0.55)]. Significant inverse signals were observed for each of the six types of SGLT2i across all intervals. This indicates that SGLT2i initiation may be associated with a decreased risk of hyperuricemia. Further investigation of the efficacy of SGLT2i is needed in hypothesis-testing designs such as cohort studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHyperuricemiaDatabases, FactualHumansMaleMiddle AgedFemaleJapanAgedDiabetes Mellitus, Type 2Uric AcidAdultEast Asian People

Stichwörter der Autor:innen

administrative claims databasehyperuricemiasequence symmetry analysissodium-glucose cotransporter 2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsUric Acid

Autor:innen und Institutionen

  • Division of Drug Informatics, School of Pharmacy, Kindai University.

Zitieren

APA

Yokoyama, S., Nakagawa, C., Uno, T., & Hosomi, K. (2024). Evaluating the Associated Hyperuricemia Risk with Sodium-Glucose Cotransporter 2 Inhibitors: A Sequence Symmetry Analysis Using the Japanese Administrative Claims Database. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00330

Vancouver

Yokoyama S, Nakagawa C, Uno T, Hosomi K. Evaluating the Associated Hyperuricemia Risk with Sodium-Glucose Cotransporter 2 Inhibitors: A Sequence Symmetry Analysis Using the Japanese Administrative Claims Database. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00330

BibTeX
@article{Yokoyama2024,
  author = {Yokoyama, Satoshi and Nakagawa, Chihiro and Uno, Takaya and Hosomi, Kouichi},
  title = {Evaluating the Associated Hyperuricemia Risk with Sodium-Glucose Cotransporter 2 Inhibitors: A Sequence Symmetry Analysis Using the Japanese Administrative Claims Database},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b24-00330}
}
Kostenlos starten →